Scientists Uncover Strange Effect Ozempic Might Have on Your Hair

Key Points:

• New research from the University of Pennsylvania indicates that GLP-1 medications like semaglutide and tirzepatide, used for type 2 diabetes and weight loss, may be associated with a small increased risk of hair loss (alopecia).
• The study analyzed medical records of about 12,000 type 2 diabetes patients newly prescribed GLP-1s between 2019 and 2024, finding GLP-1 users were 37% more likely to develop alopecia than those on SGLT-2 inhibitors and 68% more likely than those on DPP-4 inhibitors.
• The hair loss observed was primarily non-scarring alopecia, which often allows for hair regrowth, and the overall incidence was low at roughly 1.6% of GLP-1 users during the study period.
• Researchers suggest rapid or substantial weight loss induced by GLP-1s, potentially leading to nutrient deficiencies or hormonal changes, may explain the link to hair loss, but further studies are needed to clarify the mechanisms and reversibility.
• Despite the small risk, awareness of this potential side effect can help patients and doctors make informed treatment decisions, and GLP-1 drugs are now required by the FDA to list alopecia as a possible adverse reaction.